Phaseline

Companies › PeproMene Bio

PeproMene Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BAFFR-CAR T cells
BAFFR-targeting CAR T cell therapy
TNFRSF13CPhase 1Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04690595BAFFR-CAR T cellsPhase 1Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaOncologyNov 2026
NCT05370430BAFFR-CAR T cellsPhase 1Relapsed or Refractory B-cell Non-Hodgkin's LymphomaOncologyJul 2027

Targets

TNFRSF13C (1)

Companies with the same targets

Novartis Jiangsu Topcel-KH Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.